

FIG. 1

Receptor Pairing Within the Janus Kinase Family




FIG. 2

Primary Efficacy Endpoint Results of Brepocitinib

| Study Population            | Pathogenic Cytokine<br>Overlap with DM                             | Brepocitinib Dose<br>(QD) | Primary Endpoint Result (placebo<br>adjusted)<br>(N) | Statistical<br>Significance |
|-----------------------------|--------------------------------------------------------------------|---------------------------|------------------------------------------------------|-----------------------------|
| Psoriatic Arthritis         | INF-1 ( $\alpha$ , $\beta$ ), INF-II ( $\gamma$ ),<br>IL-12, IL-23 | 30 mg                     | 23.4% ACR20 RR at week 16 (N=218)                    | P = 0.0197                  |
| Plaque Psoriasis            | INF-1 ( $\alpha$ , $\beta$ ), INF-II ( $\gamma$ ),<br>IL-12, IL-23 | 30 mg                     | -10.1 CFB in PASI Score at week 12<br>(N=212)        | P < 0.0001                  |
| Ulcerative Colitis          | INF-II ( $\gamma$ ),<br>IL-12, IL-23                               | 30 mg                     | -2.28 CFB in Mayo Score at week 8<br>(N=167)         | P = 0.0005                  |
| Alopecia Areata             | INF-II ( $\gamma$ ), IL-23                                         | 30 mg                     | 49.18 CFB in SALT Score at week 24<br>(N=94)         | P < 0.0001                  |
| Hidradenitis<br>Suppurativa | INF-II ( $\gamma$ ),<br>IL-12, IL-23                               | 45 mg                     | 18.7% HiSCR Rate at week 16 (N=100)                  | P = 0.0298                  |

CFB = change from baseline; RR = response rate

FIG. 3

**Estimated Inhibition of Cytokine Signaling (%) at Average Brepocitinib Blood Concentration**





**FIG. 4**

Normalized Efficacy Response Rate Versus Average Daily Dose of Brepocitinib by Study



SALT = Severity of Alopecia Tool; HSCR = Hidradenitis Suppurativa Clinical Response;  
PASI = Psoriasis Area and Severity Index; ACR = American College of Rheumatology

FIG. 5

Disolution of Prototype Tablet (A) 30 mg Brepocitinib pH 6.8 Phosphate  
Buffer using USP Apparatus II at 75 rpm




FIG. 6

Brepocitinib Effects on IFN- $\gamma$  Induced Myotube Damage




FIG. 7

Brepocitinib Effects on IFN- $\gamma$  Induced Endothelial Cell Damage




FIG. 8

Brepocitinib 30 mg and 15 mg QD vs Tofacitinib 5 mg BID  
Inhibition of Cytokines




FIG. 9




FIG. 10